Clinical Trial: Hematopoietic Progenitor Cell Transplantation in Breast Cancer: Current Status and Future Directions

References

• Wingo P, Tong T, Bolden S. Cancer statistics. CA—A Cancer Journal for Clinicians 1995; 45: 8–30
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N. Overview of new treatments for breast cancer. Breast Cancer Res Treat 1992; 21: 3–13
   PubMed Web of Science ®Google Scholar
• Mick R, Begg C B, Antman K H, et al. Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapies?. Breast Cancer Res Treat 1989; 13: 33–38
   PubMed Web of Science ®Google Scholar
• Legha S S, Buzdar A U, Smith T L, et al. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med 1979; 91: 847–852
   PubMed Web of Science ®Google Scholar
• Greenberg P AC, Hortobagyi G N, Smith T L, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197–2205
   PubMed Web of Science ®Google Scholar
• Gregory W M, Smith P, Richards M A, et al. Chemotherapy of advanced breast cancer: Outcome and prognostic factors. Br J Cancer 1993; 68: 988–995
   PubMed Web of Science ®Google Scholar
• Fisher B, Bauer M, Margolese R, et al. Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985; 312: 665–673
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989; 320: 822–828
   PubMed Web of Science ®Google Scholar
• Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancer of the breast. N Engl J Med 1981; 305: 6–11
   PubMed Web of Science ®Google Scholar
• Valagussa P, Bonadonna G, Veronesi U. Patterns of relapse and survival following radical mastectomy: Analysis of 716 consecutive patients. Cancer 1978; 41: 1170–1178
   PubMed Web of Science ®Google Scholar
• Fisher E, Sass R, Fisher B. Pathologic findings from the national surgical adjuvant breast project for breast cancers (protocol no. 4). Cancer 1984; 53: 712–723
   PubMed Web of Science ®Google Scholar
• Nemoto T, Vana J, Bedwani R N, et al. Management and survival of female breast cancer: Results of a national survey by the American College of Surgeons. Cancer 1980; 45: 2917–2924
   PubMed Web of Science ®Google Scholar
• Clark G M, Sledge G W, Jr, Osborne C K, et al. Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987; 5: 55–61
   PubMed Web of Science ®Google Scholar
• Aisner J, Weinberg V, Perloff M, et al. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP each ± MER) for metastatic carcinoma of the breast: A CALGB study. J Clin Oncol 1987; 5: 1523–1533
   PubMed Web of Science ®Google Scholar
• Falkson G, Gelman R S, Tormey D C, et al. The Eastern Cooperative Oncology Group experience with cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 1985; 56: 219–224
   PubMed Web of Science ®Google Scholar
• Rainey J M, Jones S E, Salmon S E. Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide (VAC). Cancer 1979; 43: 66–71
   PubMed Web of Science ®Google Scholar
• Theriault R L, Hortobagyi G N, Kau S W, et al. Sequential multi-agent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. Cancer 1988; 62: 2105–2110
   PubMed Web of Science ®Google Scholar
• Henderson I C. Chemotherapy for advanced disease. Breast Diseases, J R Harris, S Hellman, I C Henderson, D W Kenne. JB Lippincott, Philadelphia 1987; 428–479
   Google Scholar
• Hortobagyi G N, Buzdar A U, Bodey G P, et al. High-dose induction chemotherapy of metastatic breast cancer in protected environment: A prospective randomized study. J Clin Oncol 1987; 5: 178–184
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 71–85
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 1995; 332: 901–906
   PubMed Web of Science ®Google Scholar
• Breast cancer. Have we lost our way? (editorial). Lancet 1993; 341: 343–344
   PubMed Web of Science ®Google Scholar
• Triozzi P L. Autologous bone marrow and peripheral blood progenitor transplant for breast cancer. Lancet 1994; 344: 418–419
   PubMed Web of Science ®Google Scholar
• Schabel F M. Animal models as predictive systems. Cancer Chemotherapy: Fundamental Concepts and Recent Advances. Year Book Medical, Chicago 1975; 323–355
   Google Scholar
• Teicher B, Holden S A, Cucchi C A, et al. Combination of N,N′,N″-triethylenefhiophosphamide and cyclophosphamide in vitro and in vivo. Cancer Res 1988; 48: 94–100
   PubMed Web of Science ®Google Scholar
• Frei E, III, Cucchi C, Rosowsky A, et al. Alkylating agent resistance: In vitro studies with human cell lines. Proc Natl Acad Sci USA 1985; 82: 2158–2162
   PubMed Web of Science ®Google Scholar
• Hyriniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar
• Frei E, III, Antman K, Teicher B, et al. Review article: Bone marrow autotransplantation for solid tumors-prospects. J Clin Oncol 1989; 7: 515–526
   PubMed Web of Science ®Google Scholar
• Frei E, III, Teicher B A, Holden S A, et al. Effect of alkylating agent dose: Studies and possible clinical correlation. Cancer Res 1988; 48: 6417–6432
   PubMed Web of Science ®Google Scholar
• DeVita V T, Jr. Dose-response is alive and well. J Clin Oncol 1986; 4: 1157–1159
   PubMed Web of Science ®Google Scholar
• Hryniuk W M. The importance of dose-intensity in the outcome of chemotherapy. Advances in Oncology, V T DeVita, Jr, S Hellman, S A Rosenberg. Lippincott, Philadelphia 1988; 121–141
   Google Scholar
• Cheson B D, Lacerna L, Leyland-Jones B, et al. Review: Autologous bone marrow transplantation: Current status and future directions. Ann Intern Med 1989; 110: 51–65
   PubMed Web of Science ®Google Scholar
• Tannock I F, Boyd N F, De Boer G, et al. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377–1387
   PubMed Web of Science ®Google Scholar
• Teicher B A, Cucci C A, Lee J B, et al. Alkylating agents: In vitro studies of cross resistance patterns in human cell lines. Cancer Res 1986; 46: 4379–4383
   PubMed Web of Science ®Google Scholar
• Hyriniuk W, Levine M N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162–1170
   PubMed Web of Science ®Google Scholar
• Bonnadonna G, Valagusa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981; 304: 10–15
   PubMed Web of Science ®Google Scholar
• Wood W C, Budman D R, Korzun A H, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994; 330: 1253–1259
   PubMed Web of Science ®Google Scholar
• Stewart T HM, Retsky M W, Tsai S CJ, et al. Dose response in the treatment of breast cancer. Lancet 1994; 343: 402–404
   PubMed Web of Science ®Google Scholar
• Skipper H E, Schabel F M, Jary R, et al. Experimental evaluation of potential antitumor agents. Cancer Chemother Rep 1964; 35: 1–111
   PubMedGoogle Scholar
• O'Dwyer P J, LaCreta F P, Schilder R, et al. Phase I trial of thiotepa in combination with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1992; 10: 1352–1358
   PubMed Web of Science ®Google Scholar
• O'Dwyer P J, LaCreta F, Engstrom P F, et al. Phase I pharmacokinetic reevaluation of thiotepa. Cancer Res 1991; 51: 3171–3176
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Reed M D, Spitzer T R, et al. High-dose IV thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 1987; 71: 689–695
   PubMedGoogle Scholar
• Antman K, Bearman S I, Davidson N, . Dose intensive therapy in breast cancer: current status. New Strategies in Bone Marrow Transplantation, R E Champlin, R P Gale, et al. Wiley-Liss, New York 1991; 423–436
   Google Scholar
• Peters W P, Eder J P, Henner W P, et al. High dose combination alkylating agents with autologous bone marrow support: A phase I trial. J Clin Oncol 1986; 4: 646–654
   PubMed Web of Science ®Google Scholar
• Antman K, Eder J P, Elias A, et al. High dose combination alkylating agent preparative regimens with autologous bone marrow support: The Dana Farber Institute/Beth Israel Hospital experience. Cancer Treat Rep 1987; 71: 119–125
   PubMedGoogle Scholar
• Slease R B, Benear J B, Selby G B, et al. High-dose combination alkylating agent therapy with autologous bone marrow rescue for refractory solid tumors. J Clin Oncol 1988; 6: 1314–1320
   PubMed Web of Science ®Google Scholar
• Eder J P, Antman K, Elias A. Cyclophosphamide and thiotepa with autologous bone marrow transplantation in patients with solid tumors. J Natl Cancer Inst 1988; 80: 1221–1226
   PubMed Web of Science ®Google Scholar
• Eder J P, Elias A, Shea T C, et al. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients. J Clin Oncol 1990; 8: 1239–1245
   PubMed Web of Science ®Google Scholar
• Moormeier J A, Williams S F, Kaminer L S, et al. High dose trialkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. J Natl Cancer Inst 1990; 82: 29–34
   PubMed Web of Science ®Google Scholar
• Schabel F M, Trader N W, Laster W R, Jr, et al. Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother 1978; 23: 200–215
   PubMedGoogle Scholar
• Schabel F M. Synergism and antagonism among antitumor agents. The Pharmacological Basis of Cancer Chemotherapy. Williams & Wilkins, Baltimore 1975; 595–623
   Google Scholar
• Thomas E D, Buckner C D, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511–533
   PubMed Web of Science ®Google Scholar
• Phillips G L, Herzig R H, Lazarus H M, et al. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation, and cryopreserved autologous marrow transplantaion. N Engl J Med 1984; 310: 1567–1571
   Google Scholar
• Cole H M. Questions and answers. Diagnostic & Therapeutic Technology Assessment (DATTA). J Am Med Assoc 1990; 263: 881–887
   Google Scholar
• Bortin M M, Horowitz M M, Gale R P, et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. J Am Med Assoc 1992; 268: 607–612
   Web of Science ®Google Scholar
• Eddy D M. Review article: High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 1992; 10: 657–670
   PubMed Web of Science ®Google Scholar
• Peters W P, Shpall E J, Jones R B, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368–1376
   PubMed Web of Science ®Google Scholar
• Antman K, Ayash L, Elias A, et al. A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102–110
   PubMed Web of Science ®Google Scholar
• Holland H K, Dix S P, Geller R B, et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156–1164
   PubMed Web of Science ®Google Scholar
• Klumpp T R, Mangan K F, Glenn L D, et al. Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 1993; 11: 337–339
   PubMed Web of Science ®Google Scholar
• Demirer T, Buckner C D, Appelbaum F R, et al. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant 1996; 17: 769–774
   PubMed Web of Science ®Google Scholar
• Kalaycioglu M E, Lichtin A E, Andresen S W, et al. High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer. Am J Clin Oncol 1995; 18: 491–494
   PubMed Web of Science ®Google Scholar
• Williams S F, Gilewski T, Mick R, et al. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: Follow-up report. J Clin Oncol 1992; 10: 1743–1747
   PubMed Web of Science ®Google Scholar
• Kennedy M J, Beveridge R A, Rowley S D, et al. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920–926
   PubMed Web of Science ®Google Scholar
• Myers S E, Mick R, Williams S F. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: A role for peripheral blood progenitor transplant. Bone Marrow Transplant 1994; 13: 449–454
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Extra J M, Lotz J P, et al. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Bone Marrow Transplant 1996; 18: 857–863
   PubMed Web of Science ®Google Scholar
• Crown J, Kritz A, Vahdat L, et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1993; 11: 1144–1149
   PubMed Web of Science ®Google Scholar
• Demagalhaes-Silverman M, Rybka W B, Lembersky B, et al. High-dose cyclophoshamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer. Am J Clin Oncol 1996; 19: 169–173
   PubMed Web of Science ®Google Scholar
• Erban J, Miller K, Berkman E, et al. High dose chemotherapy with stem cell rescue following hormonal recruitment in women with stage IIIA-1V breast cancer in remission (abstract 146). Proc Am Soc Clin Oncol 1996; 15: 120
   Google Scholar
• Fields K K, Elfenbein G J, Lazarus H M, et al. Maximum tolerated doses of ifosfamide, carboplatin, and etoposide given over six days followed by autologous stem cell rescue: Toxicity profile. J Clin Oncol 1995; 13: 323–332
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Gray R, Ciobanu N, et al. A phase I trial of high-dose melphalan, high-dose etoposide, and autologous bone marrow re-infusion in solid tumors: An Eastern Cooperative Oncology Group (ECOG) study. Bone Marrow Transplant 1994; 4: 443–448
   Google Scholar
• Weaver C H, Bensinger W I, Appelbaum F R, et al. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813–819
   PubMed Web of Science ®Google Scholar
• Stemmer S M, Cagnoni P J, Shpall E J, et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: A phase I trial. J Clin Oncol 1996; 14: 1463–1472
   PubMed Web of Science ®Google Scholar
• Broun E R, Sledge G W, Walsh W K, et al. Dose escalation of Taxol with high dose carboplatin/cyclophosphamide and PBSC support in stage IV breast cancer (abstract 1003). Proc Am Soc Clin Oncol 1996; 15: 344
   Google Scholar
• Somlo G, Doroshow J H, Forman S J, et al. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer 1994; 73: 1678–1685
   PubMed Web of Science ®Google Scholar
• Somlo G, Doroshow J H, Forman S J, et al. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell rein-fusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer 1994; 73: 125–134
   PubMed Web of Science ®Google Scholar
• Vaughan W P, Reed E C, Edwards B, Kessinger A. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: An effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant 1994; 13: 619–624
   PubMed Web of Science ®Google Scholar
• Saez R A, Selby G B, Slease R B, et al. Autologous bone marrow transplantation for metastatic breast cancer. J Okla State Med Assoc 1994; 87: 405–410
   PubMedGoogle Scholar
• Gianni A M, Siena S, Bregni M, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results. J Clin Oncol 1997; 15: 2312–2321
   PubMed Web of Science ®Google Scholar
• Peters W P, Ross M, Vredenburgh J J, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132–1143
   PubMed Web of Science ®Google Scholar
• Broun E R, Petruska P J, Dunphy F R, et al. Taxol plus carboplatin/cyclophosphamide and peripheral blood stem cell (PBSC) support in stage II/III breast cancer (abstract 1002). Proc Am Soc Clin Oncol 1996; 15: 344
   Google Scholar
• Spitzer T R, Cirenza E, McAfee S, et al. Phase III trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant 1995; 15: 537–542
   PubMed Web of Science ®Google Scholar
• Razis E D, Samonis G, Cook P, et al. TMJ: A well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer. J Med 1994; 25: 241–250
   PubMedGoogle Scholar
• Tomas J F, Perez-Carrion R, Escudero A, et al. Results of a pilot study of 40 patients using high-dose therapy with hematopoietic rescue after standard-dose adjuvant therapy for high-risk breast cancer. Bone Marrow Transplant 1997; 19: 331–336
   PubMed Web of Science ®Google Scholar
• Peters W P, Fay J W, Holland H K, et al. Autologous bone marrow transplantation as adjuvant therapy in primary breast cancer: The American experience. Bone Marrow Transplant 1995; 15(Suppl 1)S254–S259
   Google Scholar
• Livingston R B, Schulman S, Griffin B R, et al. Combination chemotherapy and systemic irradiation consolidation for poor prognosis breast cancer. Cancer 1987; 59: 1249–1254
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Lepage E, Espie M, et al. Cyclophosphamide, total body irradiation with autologous bone marrow support for metastatic breast cancer (abstract 255). Proc Am Soc Clin Oncol 1987; 6: 65
   Google Scholar
• Gisselbrecht C, Le Page E, Extra J, (1989) Inflammatory and metastatic breast cancer: cyclophosphamide and total body irradiation (TBI) with autologous bone marrow transplantation (ABMT). Autologous Bone Marrow Transplantation. Proceedings of the Fourth International Symposium. 1989, K Dicke, G Spitzer, S Jagannath, et al. Anderson Cancer Center Press, University of Texas, Houston, MD, 363–367
   Google Scholar
• Gandola L, Siena S, Bregni M, et al. Prospective evaluation of pulmonary function in cancer patients treated with total body irradiation, high-dose melphalan, and autologous hematopoietic stem cell transplantation. Int J Radiat Oncol Biol Phys 1990; 19: 743–749
   PubMed Web of Science ®Google Scholar
• Huber C, Niederwieser D, Schonitzer D, et al. Liver transplantation followed by high-dose cyclophosphamide, total-body irradiation, and autologous bone marrow transplantation for treatment of metastatic breast cancer. A case report. Transplantation 1984; 37: 311–312
   PubMed Web of Science ®Google Scholar
• Stewart P S. Autologous bone marrow transplantation in metastatic breast cancer. Breast Cancer Res Treat 1982; 2: 85–92
   PubMedGoogle Scholar
• Tutschka P J, Copelan E A, Klein J P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–1388
   PubMed Web of Science ®Google Scholar
• Avalos B, Tutschka P J, Kapoor N, et al. Busulfan and cyclophosphamide as a preparative regimen for marrow transplantation for lymphoma. Exp Hematol 1990; 18: 421–425
   PubMedGoogle Scholar
• Schiff P B, Fant J, Horwitz S B. Promotion of microtubule assembly in vitro by Taxol. Nature 1979; 177: 655–667
   Google Scholar
• Horwitz S B. Mechanism of action of Taxol. Trends Pharmacol Sci 1992; 13: 134–136
   PubMed Web of Science ®Google Scholar
• Milas L, Hunter N R, Kurdoglu B, et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother Pharmacol 1995; 35: 297–303
   PubMed Web of Science ®Google Scholar
• McCloskey D E, Davidson N E. Paclitaxel-induced programmed cell death in human breast cancer cells (abstract 2482). Proc Am Assoc Cancer Res 1995; 36: 416
   Google Scholar
• Reichman B S, Seidman A D, Crown J PA, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943–1951
   PubMed Web of Science ®Google Scholar
• Rowinsky E K, Gilbert M R, McGuire W P, et al. Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 1991; 9: 1692–1703
   PubMed Web of Science ®Google Scholar
• Rowinsky E K, Donehower R C. Paclitaxel (Taxol). N Engl J Med 1995; 332: 1004–1009
   PubMed Web of Science ®Google Scholar
• Shea T, Graham M, Bernard S, et al. Multiple cycles of high dose paclitaxel plus escalating doses of carboplatin with G-CSF (filgrastim) and peripheral blood stem cell (PBSC) support (abstract 1555). Proc Am Soc Clin Oncol 1995; 14: 478
   Google Scholar
• Fields K, Perkins J, Elfenbein G, et al. A phase I dose escalation trial of high dose Taxol, Novantrone, and thiotepa (TNT) followed by autologous stem cell rescue (ASCR): Toxicity (abstract 953). Proc Am Soc Clin Oncol 1995; 14: 322
   Google Scholar
• Falkson G, Gelman R S, Pretorius F J. Age as a prognostic factor in recurrent breast cancer. J Clin Oncol 1986; 4: 663–671
   PubMed Web of Science ®Google Scholar
• Fey M F, Brunner K W, Sonntag R W. Prognostic factors in metastatic breast cancer. Cancer Clin Trials 1981; 4: 237–247
   PubMedGoogle Scholar
• Tormey D C, Carbone P, Band P. Breast cancer survival in single and combination chemotherapy trials since 1968 (abstract). Proc Am Assoc Cancer Res 1977; 18: 64
   Web of Science ®Google Scholar
• Henderson I C. Chemotherapy for metastatic disease. Breast Diseases, J R Harris, S Hellman, I C Henderson, D W Kinne. JB Lippincott, Philadelphia 1991; 604–665
   Google Scholar
• Gradishar W J, Tallman M S, Abrams J S. High-dose chemotherapy for breast cancer. Ann Intern Med 1996; 125: 599–604
   PubMed Web of Science ®Google Scholar
• Jones V E, Raghaven D. Quantum leaps in treatment of high-risk breast cancer?. Prove it! Eur J Cancer 1993; 29A: 1488–1493
   PubMed Web of Science ®Google Scholar
• Canellos G P. Autologous bone marrow or stem cell transplantation following high-dose chemotherapy for breast cancer: What is the true story?. Breast Diseases: A Year Book Quarterly 1995; 6: 19–20
   Google Scholar
• Kennedy M J. High-dose chemotherapy of breast cancer: Is the question answered?. J Clin Oncol 1995; 13: 2477–2479
   PubMed Web of Science ®Google Scholar
• Davidson N E. Out of the courtroom and into the clinic. J Clin Oncol 1992; 10: 517–519
   PubMed Web of Science ®Google Scholar
• Bezwoda W R, Seymour L, Dansey R D. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 1995; 13: 2483–2489
   PubMed Web of Science ®Google Scholar
• Antman K H, Rowlings P A, Vaughan W P, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870–1879
   PubMed Web of Science ®Google Scholar
• Ayash L, Wheeler C, Fairclough D, et al. Prognostic factors for prolonged disease-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995; 13: 2043–2049
   PubMed Web of Science ®Google Scholar
• Dunphy F R, Spitzer G, Rossiter Fornoff J E, et al. Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer 1994; 73: 2157–2167
   PubMed Web of Science ®Google Scholar
• Bearman S I, Jones R B, Shpall E J, et al. High-dose chemotherapy with autologous progenitor cell support for stage IV NED breast cancer (abstract 194). Proc Am Soc Clin Oncol 1994; 13: 98
   Google Scholar
• Norton L. A Gompertian model of human breast cancer growth. Cancer Res 1988; 48: 7067–7071
   PubMed Web of Science ®Google Scholar
• Norton L, Simon R. Tumor size, sensitivity to therapy and the design of treatment schedules. Cancer Treat Rep 1977; 61: 1307–1317
   PubMedGoogle Scholar
• Dunphy F R, Spitzer G, Buzdar A U, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 1990; 8: 1207–1216
   PubMed Web of Science ®Google Scholar
• Pittman K B, To L B, Bayly J L, et al. Non-haematologic toxicity limiting the application of sequential high dose chemotherapy in patients with advanced breast cancer. Bone Marrow Transplant 1992; 10: 535–540
   PubMed Web of Science ®Google Scholar
• Ayash L J, Elias A, Wheeler C, et al. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: A feasibility study. J Clin Oncol 1994; 12: 37–44
   PubMed Web of Science ®Google Scholar
• Bitran J D, Samuels B, Klein L, et al. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant 1996; 17: 157–162
   PubMed Web of Science ®Google Scholar
• Broun E R, Sridhara R, Sledge G W, et al. Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 1995; 13: 2050–2055
   PubMed Web of Science ®Google Scholar
• Ho A D, Mason J, Mulroney C, et al. Sequential high-dose chemotherapy with alternating regimens and stem cell support for patients with metastatic breast cancer (abstract 188). Proc Am Soc Clin Oncol 1994; 13: 96
   Google Scholar
• Somlo G, Doroshow J H, Forman S, et al. Double cycle (C) high-dose melphalan (MEL) and cisplatin (CDDP) followed by peripheral stem cell (PSC) rescue (abstract 219). Proc Am Soc Clin Oncol 1994; 13: 104
   Google Scholar
• Crown J, Raptis G, Vahdat L, et al. Rapid administration of sequential high dose (HD) cyclophosphamide (CPA), melphalan (M), thiotepa (TT) supported by filgrastim (G) + peripheral blood progenitors (PBP) in patients (pts) with metastatic breast cancer (MBC): A novel and very active treatment strategy (abstract 242). Proc Am Soc Clin Oncol 1994; 13: 110
   Google Scholar
• Wallerstein R, Jr, Spitzer G, Dunphy F, et al. A phase II study of mitoxantrone, etoposide, and thiotepa with autologous bone marrow support for patients with relapsed breast cancer. J Clin Oncol 1990; 8: 1782–1788
   PubMed Web of Science ®Google Scholar
• Crown J, Vahdat L, Raptis G, et al. Rapidly cycled courses of high-dose (HD) chemotherapy (C) supported by filgrastim (G) and peripheral blood progenitors (PBP) in patients (pts) with metastatic breast cancer (MBC) (abstract 243). Proc Am Soc Clin Oncol 1994; 13: 110
   Google Scholar
• Ghalie R, Williams S F, Valentino L A, et al. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant 1995; 1: 40–46
   PubMedGoogle Scholar
• Kennedy M J, Armstrong D K, Huelskamp A M, et al. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol 1995; 13: 1136–1143
   PubMed Web of Science ®Google Scholar
• Kennedy M J, Armstrong D K, Bond S, et al. Phase II study of novobiocin (N) in combination with high-dose alkylating agent chemotherapy (HDC) for patients (PTS) with advanced breast cancer (BC) (abstract 966). Proc Am Soc Clin Oncol 1996; 15: 335
   Google Scholar
• Dimitrov N, Anderson S, Fisher B, et al. Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer (BC): Findings from NSABP B-22 (abstract 58). Proc Am Soc Clin Oncol 1994; 13: 64
   Google Scholar
• Bearman S I, Overmoyer B A, Bolwell B J, et al. High-dose chemotherapy with autologous peripheral blood progenitor cells (PBPC) for stage Will breast cancer in patients with 4–9 involved axillary lymph nodes (abstract 232). Proc Am Soc Clin Oncol 1995; 14: 133
   Google Scholar
• Peters W P, Jones R B, Vredenburgh J, et al. A large, prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (abstract 149). Proc Am Soc Clin Oncol 1996; 15: 121
   Google Scholar
• Brandt S J, Peters W P, Atwater S K, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988; 318: 869–876
   PubMed Web of Science ®Google Scholar
• Aurer I, Ribas A, Gale R P. What is the role of recombinant colony-stimulating factors in bone marrow transplantation?. Bone Marrow Transplant 1990; 6: 79–87
   PubMed Web of Science ®Google Scholar
• Mertelsmann R, Herrmann F, Hecht T, et al. Hematopoietic growth factors in bone marrow transplantation. Bone Marrow Transplant 1990; 6: 73–7
   PubMed Web of Science ®Google Scholar
• Körbling M, Dorken B, Ho A D, et al. Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. Blood 1986; 67: 529–532
   PubMed Web of Science ®Google Scholar
• Kessinger A, Armitage J O, Landmark J D. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71: 723–727
   PubMed Web of Science ®Google Scholar
• Lowry P A, Tabbara I A. Mini review: Peripheral hematopoietic stem cell transplantation: Current concepts. Exp Hematol 1992; 20: 937–942
   PubMed Web of Science ®Google Scholar
• Elias A D, Ayash L, Anderson K C, et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036–3044
   PubMed Web of Science ®Google Scholar
• Myers S E, Williams S F, Geller R B. Cyclophosphamide mobilization of peripheral blood stem cells for use in autologous transplant after high dose chemotherapy: Clinical results in patients with contaminated or hypocellular bone marrow. J Hematother 1992; 1: 27–33
   PubMedGoogle Scholar
• Ho A D, Glück S, Germond C, et al. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 1993; 7: 1738–1746
   PubMed Web of Science ®Google Scholar
• Williams S F. Application of peripheral blood progenitors to dose intensive therapy of breast cancer. Breast Cancer Res Treat 1993; 26(Suppl 1)25–29
   Google Scholar
• To L B, Shepperd K M, Haylock D N, et al. Single high dose of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442–447
   PubMed Web of Science ®Google Scholar
• Gianni A M, Siena S, Bregni M, et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; ii: 580–585
   Google Scholar
• Bishop M R, Anderson J R, Jackson J D, et al. High-dose therapy and peripheral blood progenitor cell transplantation: Effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994; 83: 610–616
   PubMed Web of Science ®Google Scholar
• Lacone A, Pierelli L, Quaglietta A M, et al. Survival after PBSC transplantation and comparison of engraftment speed with autologous and allogeneic marrow transplantation: Results of multi-center study. Int J Artif Organs 1993; 16(S-5)45–50
   Google Scholar
• To L B, Roberts M M, Haylock D N, et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277–284
   PubMed Web of Science ®Google Scholar
• Peters W P, Rosner G, Ross M, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709–1719
   PubMed Web of Science ®Google Scholar
• Chao N J, Schriber J R, Grimes K, et al. Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 1993; 81: 2031–2035
   PubMed Web of Science ®Google Scholar
• Sheridan W P, Begley C G, Juttner C A, et al. Effect of peripheral blood progenitor cells mobilized by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992; 339: 640–644
   PubMed Web of Science ®Google Scholar
• Janssen W E, Smilee R C, Elfenbein G J. A prospective randomized trial comparing blood- and marrow-derived stem cells for hematopoietic replacement following high-dose chemotherapy (letter). J Hematother 1995; 4: 139–140
   PubMedGoogle Scholar
• Slowman S, Danielson C, Graves V, et al. Administration of GM-/G-CSF prior to bone marrow harvest increases collection of CD34+ cells. Advances in Bone Marrow Purging and Processing: Fourth International Symposium. Wiley-Liss, New York 1994; 363–369
   Google Scholar
• Dicke K A, Hood D L, Arneson M, et al. Effects of short-term in vivo administration of G-CSF on bone marrow prior to harvesting. Exp Hematol 1997; 25: 34–38
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Horowitz M M, Nugent M L. Outcome of autotransplants in older adults (abstract 977). Proc Am Soc Clin Oncol 1996; 15: 338
   Google Scholar
• Sharp J G. Micrometastases and transplantation. J Hematother 1996; 5: 519–524
   PubMedGoogle Scholar
• Rill D R, Santana V M, Roberts W M, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380–383
   PubMed Web of Science ®Google Scholar
• Brugger W, Bross K J, Giant M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636–640
   PubMed Web of Science ®Google Scholar
• Shpall E J, Jones R B. Release of tumor cells from bone marrow. Blood 1994; 83: 623–625
   PubMed Web of Science ®Google Scholar
• Brenner M K, Rill D R, Moan R C, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85–86
   PubMed Web of Science ®Google Scholar
• Brenner M K, Rill D R. Gene marking to improve the outcome of autologous bone marrow transplantation. J Hematother 1994; 3: 33–36
   PubMedGoogle Scholar
• Grande M, Barbu V, Van Den Akker J, et al. Autologous bone marrow transplantation in ALL: relapse linked to infusion of tumor cells with the back-up marrow. Bone Marrow Transplant 1994; 14: 477–480
   PubMed Web of Science ®Google Scholar
• Sharp J G, Kessinger A, Mann S, et al. Outcome of high-dose therapy and autologous transplantation in non-Hodgkin's lymphoma based on the presence of tumor in the harvested marrow or infused hematopoietic harvest. J Clin Oncol 1996; 14: 214–219
   PubMed Web of Science ®Google Scholar
• Deisseroth A, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994; 83: 3068–3076
   PubMed Web of Science ®Google Scholar
• Moss T J, Sanders D G, Lasky L C, et al. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990; 76: 1879–1883
   PubMed Web of Science ®Google Scholar
• Lemoli R, Fortuna M. A, Motta M R, et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: Positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells. Blood 1996; 87: 1625–1634
   PubMed Web of Science ®Google Scholar
• Sharp J G, Crouse D A. Marrow contamination: detection and significance. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, J O Armitage, K H Antman. Williams & Wilkins, Baltimore 1992; 226–248
   Google Scholar
• Sharp J G, Kessinger A, Vaughan W P, et al. Detection and clinical significance of minimal tumor contamination of peripheral blood stem cell harvests. Int J Cell Cloning 1992; 10(Suppl 1)92–94
   Google Scholar
• Vaughan W P, Mann S L, Garvey J, et al. Breast cancer detected in cell culture of histologically negative bone marrow predicts systemic relapse in patients with stage I, II, III and locally recurrent disease (abstract 27). Proc Am Soc Clin Oncol 1990; 9: 9
   Google Scholar
• Ross A A, Cooper B W, Lazarus H M, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605–2610
   PubMed Web of Science ®Google Scholar
• Ybanez J, Lazarus H, Ross A, et al. Impact of occult tumor (OT) reinfusion on outcome after high-dose chemotherapy (HDC) in patients with advanced breast cancer (abstract 1532). Blood 1995; 86(Suppl 1)386a
   Google Scholar
• Fields K K, Elfenbein G J, Moscinski L C, et al. PCR detection of breast cancer cells in peripheral blood stem cell collections: Incidence and correlations (abstract 2484). Blood 1995; 86: 624a
   PubMedGoogle Scholar
• Brockstein B E, Ross A A, Moss T J, et al. Tumor cell contamination of bone marrow harvest products: Clinical consequences in a cohort of advanced-stage patients undergoing high-dose chemotherapy. I Hematother 1996; 5: 617–624
   PubMedGoogle Scholar
• Douer D, Chaiwun B, Glaspy I, et al. Analysis of peripheral blood progenitor cell (PBPC) harvests for occult breast cancer micrometastases using a sensitive immunohistochemical method (abstract 51). Proc Am Soc Clin Oncol 1993; 12: 62
   Google Scholar
• Datta Y H, Adams P T, Drobyski W R, et al. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. I Clin Oncol 1994; 12: 475–482
   PubMed Web of Science ®Google Scholar
• Passos-Coelho I, Ross A A, Davis I A, et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: Effect of ex-vivo purging with 4-hydroperoxycyclophos-phamide. Cancer Res 1994; 54: 2366–2371
   PubMed Web of Science ®Google Scholar
• Simpson S I, Vachula M, Kennedy M I, et al. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp Hematol 1995; 23: 1062–1068
   PubMed Web of Science ®Google Scholar
• Pecora A L, Lazarus H, Cooper B, et al. The incidence of breast cancer cell contamination in peripheral blood stem cell collections in relation to the mobilization regimen (abstract 1622). Blood 1996; 88(Suppl 1)408a
   Google Scholar
• Shpall E I, Lones R B, Bearman S I, et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: Influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. I Clin Oncol 1994; 12: 28–36
   PubMed Web of Science ®Google Scholar
• Passos-Coelho I, Ross A A, Kahn D I, et al. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. I Clin Oncol 1996; 14: 2569–2575
   PubMed Web of Science ®Google Scholar
• Passos-Coelho I L, Ross A A, Moss T J, et al. Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1995; 85: 1138–1143
   PubMed Web of Science ®Google Scholar
• Franklin W A, Shpall E I, Williams S, et al. Immunohistochemical detection of breast cancer cells. Breast Cancer Res Treat 1997, (in press)
   Google Scholar
• Anderson I C, Shpall E I, Leslie D S, et al. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 1989; 49: 4659–4664
   PubMed Web of Science ®Google Scholar
• Shpall E I, Lones R B, Bast R C, et al. 4-Hydroperoxycyclo-phosphamid purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high dose chemotherapy and autologous bone marrow support: A phase I trial. J Clin Oncol 1991; 9: 85–93
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Rowe I M, Goldstone A H. Does in vitro purging improve the outcome after autologous bone marrow transplantation?. I Hematotherapy 1994; 2: 457–466
   Google Scholar
• Morecki S, Pavlotzky F, Margel S, et al. Purging breast cancer cells in preparation for autologous bone marrow transplantation. Bone Marrow Transplant 1987; 1: 357–363
   PubMed Web of Science ®Google Scholar
• Shpall E I, Bast R C, Loines W T, et al. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 1991; 7: 145–151
   PubMed Web of Science ®Google Scholar
• Andrews R G, Singer I W, Bernstein I D. Human hematopoietic precursors in long-term cultures: Single CD34+ cells that lack detectable T cell, B cell, and myeloid antigens produce colony-forming cells when cultured with marrow stromal cells. I Exp Med 1990; 172: 355–361
   PubMed Web of Science ®Google Scholar
• Baum C M, Weissman I L, Tsukamoto A S, et al. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci USA 1992; 89: 804–808
   PubMedGoogle Scholar
• Civin C I, Strauss L C, Brovall C, et al. A hematopoietic progenitor cell surface antigen defined by a monoclonal antigen raised against KG-1a cells. J Immunol 1984; 133: 157–162
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Van Vlasselaer P, Huynh L, et al. Rapid debulking and CD34 enrichment of filgrastim-mobilized peripheral blood stem cells by automated density gradient centrifugation. I Hematother 1997, (in press)
   Google Scholar
• Berenson R J, Bensinger W I, Hill R S, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717–1722
   PubMed Web of Science ®Google Scholar
• Lane T A, Law P, Maruyama M, et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275–282
   PubMed Web of Science ®Google Scholar
• Kato K, Radbruch A. Isolation and characterization of CD34+ hematopoietic stem cells from human peripheral blood by high-gradient magnetic cell sorting. Cytometry 1993; 14: 384–392
   PubMedGoogle Scholar
• Mapara M Y, Korner I I, Hildebrandt M, et al. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997; 89: 337–344
   PubMed Web of Science ®Google Scholar
• Thomas T E, Van Zant G, Phillips G L, et al. Simultaneous direct purging of breast carcinoma cells and enrichment of CD34+ cells using one step high gradient magnetic cell depletion (abstract 2485). Blood 1995; 86: 624a
   PubMedGoogle Scholar
• Link H, Arseniev L, Bahre O, et al. Transplantation of allogeneic CD34+ blood cells. Blood 1996; 87: 4903–4909
   PubMed Web of Science ®Google Scholar
• Berenson R J, Shpall E J, Auditore-Hargreaves K, et al. Transplantation of CD34+ hematopoietic progenitor cells. Cancer Invest 1996; 14: 589–596
   PubMed Web of Science ®Google Scholar
• Corringham R ET, Ho A D. Rapid and sustained allogeneic transplantation using immunoselected CD34+-selected peripheral blood progenitor cells mobilized by recombinant granulocyte-and granulocyte-macrophage colony-stimulating factors. Blood 1995; 86: 2052–2054
   PubMedGoogle Scholar
• Shpall E J, Ball E D, Champlin R E, et al. A prospective, randomized phase III study using the Ceprate SC stem cell concentrator to isolate CD34+ hematopoietic progenitors for autologous marrow transplantation after high dose chemotherapy (abstract 321). Blood 1993; 82: 83a
   Web of Science ®Google Scholar
• Brugger W, Heimfeld S, Berenson R, et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl I Med 1995; 333: 283–287
   PubMed Web of Science ®Google Scholar
• Emerson S G. Ex vivo expansion of hematopoietic precursors, progenitors, and stem cells: The next generation of cellular therapies. Blood 1996; 87: 3082–3088
   PubMed Web of Science ®Google Scholar
• Szilvassy S I, Hoffman R. Enriched hematopoietic stem cells: Basic biology and clinical utility. Biol Blood Marrow Transplant 1995; 1: 3–17
   PubMedGoogle Scholar
• Williams S F, Lee W J, Bender J G, et al. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. Blood 1996; 87: 1687–1691
   PubMed Web of Science ®Google Scholar
• Champlin R, Mehra R, Gajewski J, et al. Ex vivo expanded progenitor cell transplantation in patients with breast cancer (abstract 1166). Blood 1995; 86(Suppl 1)295a
   Google Scholar
• Alcorn M J, Holyoake T L, Richmond L, et al. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 1996; 14: 1839–1847
   PubMed Web of Science ®Google Scholar
• Brugger W, Vogel W, Scheding S, et al. Epithelial tumor cells are not expanded concomitantly during cytokine-mediated ex vivo expansion of peripheral blood CD34+ progenitor cells (abstract 1165). Blood 1995; 86(Suppl 1)295a
   Google Scholar
• Stiff P J, Oldenberg D, Hsi E, et al. Successful hematopoietic engraftment following high-dose chemotherapy using only ex vivo expanded bone marrow grown in Aastrom (stromal-based) bioreactors (abstract 309). Proc Am Soc Clin Oncol 1997; 16: 88a
   Google Scholar
• Lazarus H M, Haynesworth S E, Gerson S L, et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells) [MPCs]: Implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557–564
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Haynesworth S E, Gerson S L, . Clinical trials using human bone marrow-derived mesenchymal (stromal) progenitor cells. Proceedings of the Keystone Meeting. 1996, A Keating, et al. Taos, New Mexico February, 1996
   Google Scholar
• Lazarus H M, Haynesworth S E, Gerson S L, et al. Human bone marrow-derived mesenchymal (stromal) progenitor cells [MPCs] cannot be recovered from peripheral blood progenitor cell collections. J Hematother 1997, (in press)
   PubMedGoogle Scholar
• Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501–1508
   PubMed Web of Science ®Google Scholar
• Körbling M, Przepiorka D, Huh Y O, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659–1665
   PubMed Web of Science ®Google Scholar
• Goldman J. Peripheral blood stem cells for allografting. Blood 1995; 85: 1413–1415
   PubMed Web of Science ®Google Scholar
• Russell N H, Hunter A E. Peripheral blood stem cells for allogeneic transplantation. Bone Marrow Transplant 1994; 13: 353–355
   PubMed Web of Science ®Google Scholar
• Ottinger H D, Beelen D W, Scheulen B, et al. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775–2779
   PubMed Web of Science ®Google Scholar
• Bensinger W I, Buckner C D, Shannon-Dorcy K, et al. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996; 88: 4132–4138
   PubMed Web of Science ®Google Scholar
• Koç O N, Allay J A, Lee K, et al. Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol 1996; 23: 46–65
   PubMed Web of Science ®Google Scholar
• Allay J, Dumenco L, Koç O, et al. Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood 1995; 85: 3342–3351
   PubMed Web of Science ®Google Scholar
• Flasshove M, Banerjee D, Mineishi S, et al. Ex vivo expansion and selection of human CD34+ peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 1995; 85: 566–574
   PubMed Web of Science ®Google Scholar
• Ward M, Richardson C, Pioli P, et al. Transfer and expression of the human multiple drug resistance gene in human CD34+ cells. Blood 1994; 84: 1408–1414
   PubMed Web of Science ®Google Scholar
• Sorrentino B, Brandt S, Bodine D, et al. Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 1992; 257: 99–103
   PubMed Web of Science ®Google Scholar
• Allay J A, Davis B M, Gerson S L. In-vivo enrichment of MGMT transduced murine hematopoietic progenitors by BCNU treatment of MGMT transplanted mice. Exp Hematol 1997, (in press)
   PubMed Web of Science ®Google Scholar
• O'Shaughnessy J A, Cowan K H, Wilson W, et al. Pilot study of high dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy and autologous bone marrow transplant (ABMT) with neoR-transduced bone marrow and peripheral blood stem cells in patients with metastatic breast cancer. Human Gene Therapy 1993; 4: 331–354
   PubMed Web of Science ®Google Scholar
• Hanania E G, Fu S Q, Zu Z, et al. Transduction of marrow cells before transplant with retroviral vectors which contain the multidrug resistance-1 (MDR-1) cDNA is associated with long term resistance to taxol and permits in vivo selection of genetically-modified cells after transplantation. J Invest Med 1995; 43(Suppl 2)278A
   Google Scholar
• Li M-X, Banerjee D, Zhao S, et al. Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood 1994; 83: 3403–3408
   PubMed Web of Science ®Google Scholar
• Maze R, Carney J, Kelley M, et al. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc Natl Acad Sci USA 1996; 93: 206–210
   PubMed Web of Science ®Google Scholar
• Allay J, Koç O, Davis B, et al. Retroviral-mediated gene transduction of the human alkyltransferase cDNA confers nitrosourea resistance to human hematopoietic progenitors. Clin Cancer Res 1996; 2: 1353–1359
   PubMed Web of Science ®Google Scholar
• Citron M, Schoenhaus M, Rothenberg H, et al. O6-methylgua-nine-DNA methyltransferase in normal and malignant tissue of the breast. Cancer Invest 1994; 12: 605–610
   PubMed Web of Science ®Google Scholar
• Spiro T P, Willson J KV, Haaga J, et al. O6-benzylguanine and BCNU: establishing the biochemical modulatory dose in tumor tissue for O6-alkylguanine DNA alkyltransferase directed DNA repair (abstract 362). Proc Am Soc Clin Oncol 1996; 15: 177
   Google Scholar
• Marks L B, Halperin E C, Prosnitz L R, et al. Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with 10 positive axillary lymph nodes. Int J Radiat Oncol Biol Phys 1992; 23: 1021–1026
   PubMed Web of Science ®Google Scholar
• Mundt A J, Sibley G S, Williams S, et al. Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: Implications for the use of adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 1994; 30: 151–160
   PubMed Web of Science ®Google Scholar
• Klingemann H-G, Phillips G L. Immunotherapy after bone marrow transplantation. Bone Marrow Transplant 1991; 8: 73–81
   PubMed Web of Science ®Google Scholar
• Bilgrami S, Silva M, Cardoso A, Ascensao J L, et al. Immunotherapy with autologous bone-marrow transplantation: rationale and results. Exp Hematol 1994; 22: 1039–1050
   PubMed Web of Science ®Google Scholar
• Kennedy M J, Vogelsang G B, Beveridge R A, et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow trnasplantation for breast cancer. J Clin Oncol 1993; 11: 478–484
   PubMed Web of Science ®Google Scholar
• Glazier A D, Tutschka P J, Farmer E R, et al. Graft-versus-host disease in cyclosporine A treated rats following syngeneic and autologous bone marrow reconstitution. J Exp Med 1983; 158: 1–8
   PubMed Web of Science ®Google Scholar
• Natali P G, Giacomini P, Bigotti A, et al. Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res 1983; 43: 660–668
   PubMed Web of Science ®Google Scholar
• Bernard D, Maurizis J-C, Ruse F, et al. Presence of HLA-D/DR antigens on the membrane of breast tumor cells. Clin Exp Immunol 1984; 56: 215–221
   PubMed Web of Science ®Google Scholar
• Kennedy M J, Vogelsang G B, Jones R J, et al. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994; 12: 249–257
   PubMed Web of Science ®Google Scholar
• Kennedy M J, Hess A D, Passos Coelho J-L, et al. Cyclosporine A (CsA) induces autologous graft vs. host disease (AGVHD) following high dose chemotherapy (HDC) supported with peripheral blood progenitor cell (PBPC) infusions alone (abstract 964). Proc Am Soc Clin Oncol 1996; 15: 335
   Google Scholar
• Kennedy M J, Hess A D, Passos Coelho J-L, et al. Autologous graft vs. host disease (AGVHD) as immune therapy after high dose chemotherapy (HDC) for metastatic breast cancer (MBC): medium-term follow up and comparison with historical controls (abstract 965). Proc Am Soc Clin Oncol 1996; 15: 335
   Google Scholar
• Ellis T M, McKenzie R S, Simms P E, et al. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma. J Immunol 1989; 143: 4282–4286
   PubMed Web of Science ®Google Scholar
• Balkwill F R. Interferons. Lancet 1989; i: 1060–1063
   Google Scholar
• Meyers J D, Flournoy N, Sanders J E, et al. Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. Ann Intern Med 1987; 107: 809–816
   PubMed Web of Science ®Google Scholar
• Ascensao J L, Miller K B, Bilgrami S, et al. Long-term follow up of immunotherapy with interferon (IFN) after marrow transplantation (BMT) for patients (pts) with lymphomas-Hodgkin (HD) and non-Hodgkin (NHL) (abstract 466). Blood 1996; 88(Suppl 1)119a
   Google Scholar
• Malkovsky M, Loveland B, North M, et al. Recombinant inter-leukin-2 directly augments the cytotoxicity of human monocytes. Nature 1987; 325: 262–265
   PubMed Web of Science ®Google Scholar
• Welte K, Ciobanu N, Moore M A, Mertelsmann R, et al. Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2. Blood 1984; 64: 380–385
   PubMed Web of Science ®Google Scholar
• Velardi A, Varese P, Grossi C E, et al. Cytolytic function of clonable T cells after human bone marrow transplantation. Blood 1990; 75: 1364–1369
   PubMed Web of Science ®Google Scholar
• Symann M, Bosly A, Gisselbrecht C, et al. Immune reconstitution after bone-marrow transplantation. Cancer Treat Rev 1989; 16(Suppl A)15–19
   PubMedGoogle Scholar
• Larsson E L, Joki A L, Stalhandske T. Mechanism of action of the new immunomodulator LS 2616 on T cell responses. Int J Immunopharmacol 1987; 9: 425–31
   PubMed Web of Science ®Google Scholar
• Bengtsson M, Simonsson B, Carlsson K, et al. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation: A pilot study in patients with acute myeloid leukemia. Transplantation 1982; 53: 882–888
   Web of Science ®Google Scholar
• Kalland T. Regulation of natural killer progenitors: Studies with a novel immunomodulator with distinct effects at the precursor level. J Immunol 1990; 144: 442–476
   Google Scholar
• Kalland T, Aim G, Stalhandske T. Augmentations of mouse natural killer cell activity by LS2626, a new immunomodulator. J Immunol 1985; 134: 3956–3961
   PubMed Web of Science ®Google Scholar
• Kalland T. Effects of the immunomodulator LS2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res 1986; 46: 3018–3022
   PubMed Web of Science ®Google Scholar
• Gaspari A A, Cheng S F, DiPersio J F, et al. Roquinimex-induced graft-versus-host reaction after autologous bone marrow transplantation. J Am Acad Dermatol 1995; 33: 711–717
   PubMed Web of Science ®Google Scholar
• Schrier D M, Stemmer S, Johnson T, et al. High-dose 90Y-Mx-DTPA-BrE-3 and autologous hematopoietic stem cell support for the treatment of advanced breast cancer: A phase I trial. Cancer Res 1995; 55: 5921S–5924S
   PubMed Web of Science ®Google Scholar
• Chan C M, Baratta F S, Ozzello L, et al. Monoclonal antibody BrE-3 participation in a multivariate prognostic model for infiltrating ductal carcinoma of the breast. Breast Cancer Res Treat 1994; 30: 243–261
   PubMed Web of Science ®Google Scholar
• Slamon D J, Clark G M, Wong S G, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177–182
   PubMed Web of Science ®Google Scholar
• Slamon D J, Godolphin W, Jones L A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707–712
   PubMed Web of Science ®Google Scholar
• Hynes N E. Amplification and overexpression of the erbB-2 gene in human tumors: Its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1993; 4: 19–26
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman C M, et al. Humanization of an anti-pi SS(tm)112 antibody for human cancer treatment. Proc Natl Acad Sci USA 1992; 89: 4285–4289
   PubMed Web of Science ®Google Scholar
• Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of recombinant human anti-HER2 monoclonal antibody in stage IV breast cancer: HER2 shedding dependent pharmacokinetics and antitumor activity (abstract 113). Proc Am Soc Clin Oncol 1995; 14: 103
   Google Scholar
• Hortobagyi G N, Theriault R L, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785–1791
   PubMed Web of Science ®Google Scholar
• Sasaki A, Boyce B F, Story B, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55: 3551–3557
   PubMed Web of Science ®Google Scholar
• Van der Pluijm G, Vloedgraven H, Van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 1996; 98: 698–705
   PubMed Web of Science ®Google Scholar
• Berenson J R, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488–493
   PubMed Web of Science ®Google Scholar
• Van Holten-Verzantvoort A TM, Kroon H M, Bijvoet O LM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 491–498
   PubMed Web of Science ®Google Scholar
• Foulds L. The experimental study of tumor progression: A review. Cancer Res 1954; 14: 327–339
   PubMed Web of Science ®Google Scholar
• Jendraschak E, Sage E H. Regulation of angiogenesis by SPARC and angiostatin: Implications for tumor cell biology. Semin Cancer Biol 1996; 7: 139–146
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple J, Welch W R, et al. Tumor angiogenesis and metastasis—Correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8
   PubMed Web of Science ®Google Scholar
• O'Reilly M S, Holmgren L, Chen C, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Medicine 1996; 2: 689–692
   PubMed Web of Science ®Google Scholar
• Folkman J. Clinical implications of angiogenesis research. N Engl J Med 1995; 333: 1757–1763
   PubMed Web of Science ®Google Scholar
• Ahmad A, Hart I R. Biology of tumor micrometastasis. J Hematother 1996; 5: 525–535
   PubMedGoogle Scholar
• Millar A, Brown P, Cornish A, et al. Tumor marker levels during Marimastat therapy (letter). Lancet 1996; 348: 263–264
   PubMed Web of Science ®Google Scholar
• Curtis R E, Boice J D, Jr, Stovall M, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992; 326: 1745–1751
   PubMed Web of Science ®Google Scholar
• Tallman M S, Gray R, Bennett J M, et al. Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: The Eastern Cooperative Oncology Group. J Clin Oncol 1995; 13: 1557–1563
   PubMed Web of Science ®Google Scholar
• Diamandidou E, Buzdar A U, Smith T L, et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: The University of Texas M.D. Anderson Cancer Center Experience. J Clin Oncol 1996; 14: 2722–2730
   PubMed Web of Science ®Google Scholar
• Traweek S T, Slovak M L, Nademanee A P, et al. Myelodysplasia occurring after autologous bone marrow transplantation (ABMT) for Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) (abstract 1805). Blood 1993; 82(Suppl 1)455a
   Google Scholar
• Chao N J, Nademanee A P, Long G D, et al. Importance of bone marrow cytogenetic evaluation before autologous bone marrow transplantation for Hodgkin's disease. J Clin Oncol 1991; 9: 1575–1579
   PubMed Web of Science ®Google Scholar
• Darrington D L, Vose J M, Anderson J R, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12: 2527–2534
   PubMed Web of Science ®Google Scholar
• Stone R M, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12: 2535–2542
   PubMed Web of Science ®Google Scholar
• Deeg H J. Delayed complications after bone marrow transplantation. Bone Marrow Transplantation, S J Forman, K G Blume, E D Thomas. Blackwell Scientific, Boston 1994; 538–544
   Google Scholar
• Hjermstad M J, Kaasa S. Quality of life in adult cancer patients treated with bone marrow transplantation-Review of the literature. Eur J Cancer 1995; 31A: 163–173
   PubMed Web of Science ®Google Scholar
• Stewart A, Hays R, Ware J. The MOS short-form general health survey: Reliability and validity in a patient population. Med Care 1988; 26: 724–735
   PubMed Web of Science ®Google Scholar
• McCorkle R, Young K. Development of a symptom distress scale. Cancer Nurs 1978; 1: 373–378
   PubMedGoogle Scholar
• Cassileth B, Lusk E, Brown L, et al. Psychological status of cancer patients and next of kin: Normative data from the profile of mood states. J Psychosoc Oncol 1985; 3: 99–105
   Google Scholar
• Greer S, Moorey S, Watson M. Patients adjustment to cancer: The mental adjustment to cancer (MAC) scale vs clinical rating. J Psychosomat Res 1989; 33: 373–377
   PubMed Web of Science ®Google Scholar
• Bergner M, Bobbitt R A, Carter W B, et al. The Sickness Impact Profile: Development and final revisions of a health status measure. Med Care 1981; 19: 787–805
   PubMed Web of Science ®Google Scholar
• Derogatis L R. The Psychological Adjustment to Illness Scale (PAIS). J Psychosom Res 1986; 30: 77–91
   PubMed Web of Science ®Google Scholar
• Schipper H, Clinch J, McMurray A, et al. Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: development and validation. J Clin Oncol 1984; 2: 472–483
   PubMed Web of Science ®Google Scholar
• Ware J E, Snow K K, Kosinski M, et al. SF-36 Health Survey: Manual and Interpretation Guide. The Health Institute, New England Medical Center, Boston 1993
   Google Scholar
• McHorney C A, Ware J E, Raczek A E. The MOS 36-item short Form Health Survey (SF-36): Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 3: 247–263
   Web of Science ®Google Scholar
• Portenoy R K, Thaler H T, Kornblith A B, et al. The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics, and distress. Eur J Cancer 1994; 30A: 1326–1336
   PubMed Web of Science ®Google Scholar
• McQuellon R P, Russell G B, Cella D F, et al. Quality of life measurement in bone marrow transplantation: Development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 1997; 19: 357–368
   PubMed Web of Science ®Google Scholar
• Winer E, Lindley C, Hardee M, et al. Quality of life (QL) assessment in patients with breast cancer surviving 12 months or more following high dose chemotherapy with autologous bone marrow transplant (HDC-ABMT) (abstract 1328). Proc Am Soc Clin Oncol 1992; 11: 383
   Google Scholar
• Hann D M, Jacobsen P B, Martin S C, et al. Quality of life following bone marrow transplantation for breast cancer: A comparative study. Bone Marrow Transplant 1997; 19: 257–264
   PubMed Web of Science ®Google Scholar
• Hillner B E, Smith T J, Desch C E. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer: Estimates using decision analysis while awaiting clinical trial results. J Am Med Assoc 1992; 267: 2055–2061
   PubMed Web of Science ®Google Scholar
• Patient Referral to the National Cancer Institute's Autologous Bone Marrow Transplantation Clinical Trials (1995) . The Physician's Perspective. A Report on Focus Groups and In-Depth Interviews Conducted at the American Society of Clinical Oncology National Meeting. May, 1995. Office of Cancer Communications, National Cancer Institute, Bethesda, MD
   Google Scholar
• McQuellon R P, Muss H B, Hoffman S L, et al. Patient preferences for treatment of metastastic breast cancer: A study of women with early-stage breast cancer. J Clin Oncol 1995; 13: 858–868
   PubMed Web of Science ®Google Scholar
• Mathews J. NCI survey explores the M.D.'s perspective on ABMT trials. J Natl Cancer Inst 1995; 87: 1510–1511
   PubMed Web of Science ®Google Scholar
• Hadorn D C. Setting health care priorities in Oregon: Cost-effectiveness meets the rule of rescue. J Am Med Assoc 1991; 265: 2218–2225
   PubMed Web of Science ®Google Scholar
• Peters W P, Rogers M C. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med 1994; 330: 473–477
   PubMed Web of Science ®Google Scholar
• Light D W. Life, death, and the insurance companies. N Engl J Med 1994; 330: 498–500
   PubMed Web of Science ®Google Scholar
• Richards M A, Braysher S, Gregory W M, et al. Advanced breast cancer: Use of resources and cost implications. Br J Cancer 1993; 67: 856–860
   PubMed Web of Science ®Google Scholar
• Gilbert C J. Peripheral blood progenitor cell transplantation for breast cancer: pharmacoeconomic considerations. Pharmacotherapy 1996; 16: 101S–108S
   PubMed Web of Science ®Google Scholar
• Lawless G D. Cost-effectiveness of autologous bone marrow transplantation. Am J Health System Pharm 1995; 52(Suppl 4)S11–S14
   PubMedGoogle Scholar
• Dillman R O, Barth N M, Mahdavi K, et al. The integration of high-dose chemotherapy and biotherapy: Initial 5-year experience with autologous bone marrow transplantation in a comprehensive community cancer center. Cancer Biother 1995; 10: 25–36
   PubMedGoogle Scholar
• Peters W P, Ross M, Vredenburgh J J, et al. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21(4 Suppl 7)25–31
   PubMed Web of Science ®Google Scholar
• Ross M, Dukelow K, Kasprzak S, et al. Outpatient bone marrow transplantation: Two year update (abstract 930). Proc Am Soc Clin Oncol 1995; 14: 316
   Google Scholar
• Meisenberg B R, Miller W E, McMillan R, et al. Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997; 15: 11–17
   PubMed Web of Science ®Google Scholar
• Schulman K A, Glick H A. Economic evaluation of high-dose chemotherapy and bone marrow transplantation for patients with breast cancer of stage II or III A with more than 10 positive lymph nodes at surgical excision. Monogr Natl Cancer Inst 1995; 19: 45–50
   PubMedGoogle Scholar
• Welch H G, Larson E B. Cost effectiveness of bone marrow transplantation in acute nonlymphocytic leukemia. N Engl J Med 1989; 321: 807–812
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Martelli M, Vignetti M, Zinzani P L, et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: A prospective randomized Italian multicenter study. J Clin Oncol 1996; 14: 534–542
   PubMed Web of Science ®Google Scholar
• Verdonck L F, Van Putten W LJ, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045–1051
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. J Clin Oncol 1994; 12: 2543–2551
   PubMed Web of Science ®Google Scholar